A Phase 2 open label, study to determine the safety, efficacy and pharmacokinetic profile of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne Muscular Dystrophy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Mar 2022 According to an Antisense Therapeutics media release, data will be presented at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
11 Jun 2020 According to an Antisense Therapeutics media release, data from this trial will be presented as a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.
21 May 2020 According to an Antisense Therapeutics media release, the company will present trial results in a webinar to be held at 9:00AM (AEST) on Friday 22 May | UK 12AM | US PDT 4:00PM: EDT 7.00PM (Thursday 21 May) https://us02web.zoom.us/webinar/register/WN_DCVk0mvJQr28qqHviPLG-Q

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com